Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 29, 2008. The report discloses dealings by persons with interests in securities representing 1% or more, pursuant to Rule 8.3 of the Takeover Code. The filing specifically addresses GSK's holdings in CeNeS Pharmaceuticals plc.
Key Financial Metrics
This filing is a regulatory disclosure regarding share ownership and does not contain financial performance data. Consequently, the following metrics are not provided in the source text:
- Revenue, profit, and cash flow
- Profit margins
- Debt and liquidity positions
Shareholding Data: Following the dealing on May 29, 2008, GSK and its subsidiaries held a long position of 563,568 Ordinary 30p shares in CeNeS Pharmaceuticals plc, representing 2.56% of the relevant securities. No short positions or derivatives were reported.
Material Changes
The filing details a specific transaction under "Other dealings":
- Transaction Type: Issue of shares.
- Quantity: 120,752 Ordinary shares of 30p each.
- Context: Issued pursuant to a share exchange agreement dated November 21, 2003, between CeNeS Pharmaceuticals plc and GlaxoSmithKline.
- Price: Not applicable.
No purchases, sales, or derivative transactions were recorded for the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or risk factors. It is strictly a disclosure of share dealings and ownership percentages. No agreements, arrangements, or understandings relating to voting rights or future acquisition/disposal of securities were disclosed.
Investor Verification Checklist
- Verify the total outstanding share count of CeNeS Pharmaceuticals plc to confirm the 2.56% ownership stake calculation.
- Review the original share exchange agreement dated November 21, 2003, to understand the terms triggering the issuance of 120,752 shares.
- Confirm whether CeNeS Pharmaceuticals plc is a material subsidiary or investment relative to GSK's total portfolio.